Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 9, 2016

Imago BioSciences begins enrolment for Phase I/II study of IMG-7289 to treat AML and MDS

US-based pharmaceutical company Imago BioSciences has begun enrolment for its Phase I/II study of IMG-7289 to treat high-risk acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS).

US-based pharmaceutical company Imago BioSciences has begun enrolment for its Phase I/II study of IMG-7289 to treat high-risk acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS).

The Phase I/II study is being conducted to test the safety and determine the pharmacokinetics, pharmacodynamics profile and anti-neoplastic activity of IMG-7289.

The Phase I portion of the study will use both the dose-escalation and duration-extension cohorts to test IMG-7289 as a single agent and IMG-7289 in combination with all-trans retinoic acid (ATRA).

Patients will be enrolled into the Phase II expansion arm to evaluate the longer-term anti-tumour activity exhibited by IMG-7289.

"This study will provide us with valuable data on the safety, biomarker effects and activity of this novel agent both alone and in combination with all-trans retinoic acid (ATRA)."

The study is planning to enrol about 30 patients and is being carried out at six sites.

Imago BioSciences CEO Hugh Young Rienhoff said: "We are encouraged by the progress of this programme.  

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

"This study will provide us with valuable data on the safety, biomarker effects and activity of this novel agent both alone and in combination with all-trans retinoic acid (ATRA).

"In non-clinical models, IMG-7289 has demonstrated potent anti-tumour activity against neoplastic myeloid cells, especially AML cells. These effects were synergised in combination with ATRA."

Imago BioSciences has developed IMG-7289 as a small molecule designed to inhibit lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme considered vital in cancer stem cells, particularly malignant bone marrow cells. 

IMG-7289 has exhibited in-vivo anti-tumour efficacy in non-clinical studies across a range of myeloid malignancies as a single agent and in combination with other chemotherapeutic agents.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU